A NEW CLASS OF THE ANTI-ISCHEMIC MEDICAMENTS - METABOLIC CYTOPROTECTIVE OF THE CARDIOMYOCYTE

A great imporfance of The coronary disease makes welcome any rationalinnovation in the therapy as is the case with a group of medicaments for the myocardecytoprotection primary!y by the metabolic effect; the best known of them istrimethazidine. The demand for it is obvious since even about 40% of the patientssuffering from a coronary disease tend to have residual ischemia despite the fact that the me icaments lead lo the loss of anginous symptoms. Since there are no papers ontrimethazidine (except for ours) in domestic journals, the aim of the paper is to give asurvey of contemporary literature dealing with it, to report on six years' experiencewith the safe application of trimethazidine and to analyze its effect upon the basicparameters of chemodynamics.Numerous double-blind studies point to the efficiency of this medicament thatis comparable to that of thc basic anti-ischemic medicaments. Trimethazidine canreinforce the effect of other medicaments. We conclude that it is possible, to acceptthe suggestion about the benefits of the metabolic myocarde cytoprotective from themedicine publications since the medicament can be exceptionally well endured andthat is of especial importance for hypotensive coronary patients.